Digg icon reddit icon Stumbleupon icon
Print Email     Print Edition Stories

Wednesday, October 14, 2009

Dainippon Sumitomo completes Sepracor tender offer

By Mass High Tech staff

Dainippon Sumitomo Pharma Co. has completed its previously announced tender offer for Sepracor Inc.’s outstanding shares at $23 cash per share.

The offer for 86.9 million shares, about 78.2 percent, was conducted through DSP’s wholly owned subsidiary Aption Inc., with another 13.9 shares tendered through notices of guaranteed delivery.

Sepracor (Nasdaq: SEPR) confirmed rumors of its acquisition in September. The Marlborough-based developer of sleep aid Lunesta will be run as a subsidiary of Dainippon Sumitomo and will remain in Massachusetts. In addition to Lunesta, Sepracor develops an asthma treatment Xopenex.

Dainippon Sumitomo officials said that they deal would give them access Sepracor’s expertise in helping bring Dainippon Sumitomo’s own schizophrenia drug, lurasidone, which is in Phase 3 clinical development, to approval and market.



 

Comments

If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.

Digg icon reddit icon Stumbleupon icon
Contact Editor Latest News

Tech Pulse Poll

What's your level of interest in Pinterest?



View Results

Stay Informed
Check which newsletter you'd like to receive.
TechFlash (Daily)
BioFlash (Daily)
GreenFlash (Weekly)
Startup Report (Weekly)
Breaking news, MHT events, local announcements
RSS feeds
Your email:

Affiliate publications: ACBJ.com, Boston Business Journal, Bizjournals.com, Portfolio.com, Wired.com

Web Site Developed by Neptune Web, Inc.

Use of and/or registration on any portion of this site constitutes acceptance of our User Agreement and Privacy Policy. About our ads.